PRECISION BIOSCIENCES INC 8-K

What Happened

• Precision BioSciences, Inc. filed a Current Report on Form 8-K on July 1, 2026 to update its corporate presentation (posted on the company’s Investors page). The deck highlights clinical results from PBGENE-HBV (ELIMINATE-B study), reporting a 1‑log (10-fold) reduction in cccDNA-derived transcripts consistent with direct elimination of cccDNA. The company also announced activation of a second clinical site at Washington University School of Medicine in St. Louis for the FUNCTION-DMD trial of PBGENE-DMD. Precision Bio is targeting year-end 2026 for the next program update and for initial safety data from the DMD study.

Key Details

• Filing date: July 1, 2026 (Form 8-K; Regulation FD disclosure).
• PBGENE-HBV (ELIMINATE-B): liver biopsy data show a 1‑log reduction in cccDNA-derived transcripts, attributed to direct cccDNA elimination.
• FUNCTION-DMD: second clinical site activated at Washington University School of Medicine (St. Louis); initial safety data targeted for year-end 2026.
• Corporate deck available on the company’s Investors page: https://investor.precisionbiosciences.com

Why It Matters

• A reported 1‑log reduction in cccDNA-derived transcripts is a concrete early clinical signal for PBGENE-HBV’s mechanism of action; investors often view biopsy-based biomarker changes as meaningful proof-of-concept for antiviral gene therapies.
• Activation of an additional DMD trial site indicates recruitment and trial execution momentum for PBGENE-DMD; the year-end 2026 timing for safety and program updates sets near-term clinical milestones that could be catalysts for the stock.
• The filing contains standard forward-looking statement caution: timelines and outcomes are subject to risks described in the company’s SEC filings.